Aimovig (erenumab) is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks1. It is available as an AutoInjector pen containing 70mg/ml or 140mg/ml